Electrophysiological effects of short-term antihypertensive therapy

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 10, 2008, Pages 1343-1346

  Ferri, Claudio ^a   Pasqualetti, Paolo ^a   Tiberti, Sergio ^a   Grassi, Davide ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Amlodipine; Bisoprolol; Hydrochlorothiazide; Left ventricular hypertrophy; Losartan

Indexed keywords

AMLODIPINE; BISOPROLOL; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE VARIABILITY; HEART REPOLARIZATION; HUMAN; HYPERTENSION; MALE; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY;

EID: 69849094259     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.10.1343     Document Type: Article

References (27)

1. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am. J. Cardiol. 60, 560-565 (1987).
2. McLenachan M, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N. Engl. J. Med. 317, 787-792 (1987).
3. Schillaci G, Verdecchia P, Borgioni C et al. Association between persistent pressure overload and ventricular arrhythmias in essential hypertension. Hypertension 28, 284-289 (1996).
4. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol. 32, 1454-1459 (1998).
5. Okin PM, Wachtell K, Devereux RB et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296(10), 1242-1248 (2006).
6. Porthan K, Viitasalo M, Hiltunen TP et al. Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. Ann. Med. DOI:10.1080/ 07853890802195211 (2008).
7. Ainscough JF, Drinkhill MJ, Sedo A et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc. Res. DOI:10.1093/ cvr/cvn230 (2008).
8. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail. Rev. 13(3), 367-375 (2008).
9. Delpon E, Caballero R, Gomez R, Nunez L, Tamargo J. Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol. Sci. 26, 155-161 (2005).
10. Viitasalo M, Oikarinen L, Swan H et al. Effects of β-blocker therapy on ventricular repolarization documented by 24-h electrocardiography in patients with type 1 long-QT syndrome. J. Am. Coll. Cardiol. 48, 747-753 (2006).
11. Siscovick DS, Raghunathan TE, Psaty BM et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N. Engl. J. Med. 330, 1852-1857 (1994).
12. Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (the GENRES study). Am. J. Hypertens. 20, 311-318 (2007).
13. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57, 450-458 (1986).
14. Liu JE, Devereux RB. Clinical assessment of cardiac hypertrophy. In: Left Ventricular Hypertrophy. Sheridan DJ (Ed.). Churchill Livingstone, London, UK (1998).
15. Karjalainen J, Viitasalo M, Mänttäri M, Manninen V. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J. Am. Coll. Cardiol. 23, 1547-1553 (1994).
16. Yiu KH, Tse HF. Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications. J. Hum. Hypertens. 22(6), 380-388 (2008).
17. Messerli FH. Hypertension and sudden cardiac death. Am. J. Hypertens. 12(3), 181S-188S (1999).
18. Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 116(7), 700-705 (2007).
19. Okin PM, Devereux RB, Jern S et al.; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292(19), 2343-2349 (2004).
20. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin - angiotensin system. Annu. Rev. Physiol. 54, 227-241 (1992).
21. +) currents. Circulation 101(10), 1199-1205 (2000).
22. Zicha S, Tsuji Y, Shiroshita-Takeshita A, Nattel S. β-blockers as antiarrhythmic agents. Handb. Exp. Pharmacol. 171, 235-266 (2006).
23. Blumenfeld JD, Sealey JE, Mann SJ et al. β-adrenergic receptor blockade as a therapeutic approach for suppressing the renin - angiotensin - aldosterone system in normotensive and hypertensive subjects. Am. J. Hypertens. 12(5), 451-459 (1999).
24. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J. Am. Coll. Cardiol. 43(2), 155-161 (2004).
25. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100(12), 1311-1315 (1999).
26. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
27. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265(24), 3255-3264 (1991).